Role of Icosapent Ethyl (IPE) in Patients with ASCVD Risk Factors

Evaluate the potential clinical value of recent, large-scale clinical trials on the management of patients at high risk of having ASCVD events.

1.00 available credits

Evaluate the potential clinical value of recent, large-scale clinical trials on the management of patients at high risk of having ASCVD events.

1.00 available credits
Enroll in this meeting
April 03, 2020
11:45 AM - 01:15 PM CEST
Trade Fair and Congress Center of Malaga
Room: Dali, Ground Floor, Malaga, Spain
Enrollment Fee: Free
Free
  • Overview

    This symposium provides an opportunity for participants to accurately evaluate the potential clinical value of recent, large-scale randomized clinical trials on the management of patients at high risk of having atherosclerotic cardiovascular disease (ASCVD) events. One of those trials, the REDUCE-IT trial, showed dramatic reductions in ASCVD events for patients with clinical ASCVD or diabetes and ≥1 risk factor, and the use of icosapent ethyl in these patients have recently been recommended in several guidelines. Amidst this progress in translational science, clinicians have several important issues to address regarding icosapent ethyl use so that the full benefit of the science is realized in clinical management.

     

  • Program Schedule*

    1145-1215         

    Registration, Lunch

     

     

    1215-1220

    Welcome, Introductions, Program Overview
    Børge G. Nordestgaard, MD, DMSc

     

     

    1220-1245

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Michel Farnier, MD, PhD

     

     

    1245-1310

    Mechanisms and Comparisons of Omega-3s
    Børge G. Nordestgaard, MD, DMSc

     

     

    1310-1315

    Panel Discussion, Question & Answers
    Michel Farnier, MD, PhD
    Børge G. Nordestgaard, MD, DMSc

     

     

    1315

    Closing Comments, Adjourn
    BørgeG. Nordestgaard, MD, DMSc

  • Learning Objectives

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This educational activity is designed for preventive/clinical cardiologists, endocrinologists, internists, general practitioners, and all other healthcare professionals, including, researchers and policy makers involved in cardiovascular preventions, primary care and rehabilitation.

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Global Learning Collaborative (GLC) and Medtelligence. GLC is accredited by the ACCME to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Jessica McGrory prior to the live event at jmcgrory@omnia-prova.com.

     

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free